ISLAMABAD The National Command and Operation Centre (NCOC) has decided to reinstate the required testing of 2% of incoming passengers due to growing fears over the spread of a new COVID-19 form, as reported by The News on Thursday.
Testing will assist in identifying and averting JN.One subtype of COVID-19.
But later on, reports surfaced about the paucity of testing kits and Personal Protection Equipment (PPE) at major airports like Islamabad and Karachi, officials informed the publication.
detect the”On the directives of caretaker federal Health Minister Dr. Nadeem Jan, surveillance at the country’s points of entry, including airports, has increased, and 2 percent of mandatory testing for COVID-19 has been resumed to detect the JN.1 variant of SARS-CoV-2, or coronavirus,” the official with the NCOC told The News on Wednesday.
Paradoxically, the medical staff affiliated with Border Health Services (BHS) could not obtain the PPE or the COVID-19 testing kits at any of the multiple points of entry. Officials stated that once the World Health Organization (WHO) ruled in June of this year that COVID-19 was no longer a public health emergency of global significance, neither the kits nor the personal protective equipment (PPE) were purchased.
Despite the nation’s still-extremely-low COVID-19 positive rate and the absence of any JN cases,. Up until Wednesday, just one version had been identified. As a result, the National Institutes of Health (NIH) released a warning for JN prevention and control.One sub-variant.
The World Health Organization (WHO) was cited in the NIH advice, which stated that the JN.1 sub-variant is essentially a branch of the BA.2.86 sub-variant of the COVID-19 omicron variant and has been designated as a Variant of Interest (VOI). US-CDC released their initial study on it in August 2023.
The National Institutes of Health (NIH) advisory stated that JN.1 has been reported in several countries in recent weeks and that its prevalence is rapidly rising worldwide. It further stated that this rapid growth is being observed across the three WHO regions—the Americas, the Western Pacific, and the European region—with the Western Pacific region showing the largest increase, from 1.1% in epidemiological week 44 to 65.6% in epidemiological week 48.
As per the NIH, “the purpose of this advisory is to notify and assist the health authorities and other relevant parties in guaranteeing prompt preventive and control measures, including readiness to manage the augmented workload anticipated in the outpatient and inpatient departments over the next few weeks.”
The National Institute of Health went on to say that even though JN.1 is quickly displacing other subvariants and is predicted to have a high transmissibility, it is unlikely to result in a situation similar to the pandemic’s early stages, which is why current statistics show that its morbidity and mortality are low.
The clinical presentation of JN.1 infection is comparable to that of other sub-variants, exhibiting symptoms such as headache, muscle aches, runny nose, sneezing, cough, sore throat, congestion, exhaustion, and an altered sense of smell.
The manifestation of symptoms is contingent upon an individual’s immunity to prior infections and vaccinations. The statement said, “It’s critical to understand that current vaccinations, diagnostics, and therapies are still effective against JN.1.
In addition, the NIH Islamabad said that although JN.1 infections are increasing quickly, the few pieces of data that are currently available do not indicate that the associated illness severity is greater than that of other circulating variations. It did this by citing the WHO’s overall risk assessment. It further said that current vaccinations provide the same level of protection against this JN.1 sub-variant as they do against other variations.
